Bausch Health (BHC) Deal for Synergy Assets 'Makes Strategic Sense' - Mizuho

Bausch Health (BHC) Deal for Synergy is Nothing Special - Wells Fargo's Maris

Wells Fargo analyst David Maris weighed in on Bausch Health Companies (NYSE: BHC) after the company announced today that it plans to acquire certain assets of Synergy.

Maris said while the market likes the deal, they do not expect that a marketed... More

Bausch Health (BHC) Confirms 'Stalking Horse' Agreement to Acquire Substantially All Assets of Synergy Pharmaceuticals (SGYP)

Bausch Health Companies Inc. (NYSE: BHC) announced today that it has entered into a definitive agreement to acquire certain assets of Synergy Pharmaceuticals Inc. (NASD: SGYP) ("Synergy") in a transaction valued at approximately $200 million plus certain assumed liabilities. Synergy filed a voluntary petition for reorganization under Chapter 11 of the U.S. Code (the "Bankruptcy Code") with the U.S. Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court") earlier today. Under the terms of the agreement, and subject to Bankruptcy Court approval, Bausch Health... More

Synergy Pharma (SGYP) Files Chapter 11, to Sell Most Assets to Bausch Health (BHC) for $200M

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) announced an agreement with Bausch Health Companies Inc. (NYSE: BHC), through which Bausch Health would acquire substantially all of Synergy's assets, including all rights to TRULANCE® (plecanatide), dolcanatide and related intellectual property, for approximately $200 million in cash, subject to certain adjustments at closing, plus the assumption of certain liabilities related to the assets to be acquired. The sale is subject to a competitive process and the Company's receipt of higher and better offers.

To facilitate the sale and address its debt... More